Sleeve gastrectomy outperforms tirzepatide at 12 months in matched minority cohort

The wire

1. 01In a propensity score matched single-centre cohort, sleeve gastrectomy patients lost 30% of total body weight and 12 kg/m2 of BMI at 12 months, versus 12% and 7 kg/m2 for tirzepatide.
2. 02Authors note most incretin trials lack ethnic diversity, and frame tirzepatide as a non-invasive alternative where cost, patient preference and metabolic goals drive the choice.
3. 03Retrospective design, one centre and selected matched patients limit the comparison; differences were statistically significant at 3, 6 and 12 months in linear mixed models.

From the source

Weight-Loss Outcomes After Sleeve Gastrectomy Versus Tirzepatide in a Minority Cohort With Severe Obesity: Results From a Propensity Score Matched Cohort

Clinical obesity · 2026 Dec · Manueli Laos EG, Fontaine-Nicola A, Serafica B et al.